Circulating Progenitors in Healthy Runners after Endurance and Maximal Exercise

2007

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2…

2009

AbstractData from the Italian Hemophilia Centres were collected to perform a retrospective survey of joint arthroplasty in patients with severe hemophilia. Twenty-nine of 49 hemophilia centers reported that 328 of the 347 operations were carried out in 253 patients with severe hemophilia A (HA) and 19 in 15 patients with severe hemophilia B (HB). When results were normalized to the whole Italian hemophilia population (1770 severe HA and 319 severe HB), patients with HA had a 3-fold higher risk of undergoing joint arthroplasty (odds ratio [OR], 3.38; 95% confidence interval [CI], 1.97-5.77; P < .001). These results were confirmed after adjustment for age, HIV, hepatitis C virus (HCV), and…

BONE-MARROW DERIVED HEMATOPOIETIC AND ENDOTHELIAL PROGENITORS AND RETICULOCYTES AFTER AEROBIC AND ANAEROBIC EXERCICE IN ATHLETS

2006

Release of bone-marrow derived hematopoietic and endothelial progenitors after a marathon race

2006

Could alanine/EPR dosimetry be useful for ultra-high dose rate beams used for FLASH radiotherapy?

In the last years a large interest has aroused towards radiation therapy treatments with dose rates much larger with respect to the conventional ones since experiments support the evidence of a considerable normal tissue sparing effect. Indeed, in-vivo experiments showed an increasing of the therapeutic window for dose rates over 50 Gy/s [2]. If confirmed, the ‘FLASH effect’ has the potential to re-shape the future of radiation treatments, with a significant impact on many oncology patients. Significant dosimetric challenges should be dealt with for Ultra-high dose rate (UHDR) beams for FLASH radiotherapy [4]. In particular, ionization chambers are affected by ion recombination effects, alt…

Release of bone marrow derivied hemopoietic and endothelial progenitors after a marathon race.

2006

Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis

2008

Demographic and clinical data in acquired hemophilia A

2012

Summary.  Background:  Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding. Although data on several AHA cohorts have been collected, limited information is available on the optimal management of AHA. Objectives:  The European Acquired Hemophilia Registry (EACH2) was established to generate a prospective, large-scale, pan-European database on demographics, diagnosis, underlying disorders, bleeding characteristics, treatment and outcome of AHA patients. Results:  Five hundred and one (266 male, 235 female) patients from …

Prolonged Response of Chronic Immune Thrombocytopenic Purpura (ITP) to Extracorporeal Immunoadsorption

2000

Low circulating CD34+ cells in chronic obstructive pulmonary disease (COPD)

2005

Dosimetric characterization of an ultra-high dose rate beam for FLASH radiotherapy through alanine EPR dosimetry

2022

Experimental evidence is growing, supporting the evidence of a considerable normal tissue sparing effect when treatments are delivered with dose rates much larger with respect to the conventional ones [1]. In particular, an increasing of the therapeutic window has been demonstrated for dose rates over 50 Gy/s, over a large variety of in-vivo experiments [2]. If confirmed, the ‘FLASH effect’ has the potential to re-shape the future of radiation treatments, with a significant impact on many oncology patients [3]. Ultra-high dose rate (UHDR) beams for FLASH radiotherapy present significant dosimetric challenges [4]. Ionization chambers are affected by ion recombination effects, although novel …

Sindromi emorragiche e tromboemorragiche nella patologia oncoematologica e nel trapianto di midollo

2004

Il tromboembolismo venoso in oncoematologia

2004

Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in a Mediterranean area.

2001

Abstract Background. Thromboembolism has been reported to be associated with inflammatory bowel disease. Aim. To evaluate the association of factor V Leiden and prothrombin gene mutation with inflammatory bowel disease in a population of patients with thromboembolic events and inflammatory bowel disease and in a control population of patients with inflammatory bowel disease without thromboembolic events. Patients and methods. A series of 18 patients with inflammatory bowel disease and a history of arterial or venous thrombosis and 45 patients with inflammatory bowel disease without thromboembolic events were evaluated for the presence of factor V Leiden and prothrombin gene mutation. Freque…